preirabine (MB07133) / Ligand, Xi’an XinTong Pharma - LARVOL DELTA

Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - P1/2 | N=39 | Recruiting | Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd.

New P1/2 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=91 | Recruiting | Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd.

New P2 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Immunotherapy following relapse of acute leukaemia after T-cell-replete allogeneic peripheral blood progenitor cell transplantation: importance of new onset chronic graft-versus-host disease (Int J Lab Hematol.) - P=NA, N=13; PMID: 24112249; “With a median follow-up of 47 months, the median overall survival (OS) of the non-DLI and G-DLI groups was not statistically different (8 months vs. 9 months, respectively, P = 0.5). Survival at 3 years was <10% in both groups. Univariate analysis identified response to FLAG, and new onset chronic GVHD as the only factors associated with improved OS.”

Retrospective data • Graft versus Host Disease

SAFETY,TOLERABILITY AND EFFICACY OF MB07133, A LIVER-TARGETED PRODRUG OF ARACMP, IN PATIENTS WITH PRIMARY LIVER CANCER (AASLD 2019) - "We report two Phase I studies of MB07133 that is a liver-targeted prodrug of cytarabine 5'-monophosphate (araCMP), using the HepDirectTM technology that enables drugs to be targeted to the liver. Findings from the two studies reported are well consistent witheach other. They all demonstrated that MB07133 is well tolerable and effective in patients with primary liver cancer, especially digestive side effects are milder.It might be an additional treatment option for primary liver cancer patients. The product is undergoing further assessment in the forthcoming phase II/III trials."

Clinical